news-med.jpg

Evotec signs agreement with Sanofi to advance early stage academic research into novel therapeutic candidates

The creation of LAB031 is designed to translate academic research into drug discovery candidates Evotec aims to generate multiple lead candidates for Sanofi over three years across multiple therapeutic categories

Topics: Corporate, Evotec, Sanofi, LAB031, BRIDGE Read More

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development

Hamburg, Germany, 03 July 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research ...

Topics: Corporate, Evotec, Sanofi, infectious diseases Read More

Evotec achieves second milestone in diabetes alliance with Sanofi

Companies are at the forefront of beta cell replacement therapeutic research for diabetes Evotec receives € 3 Million payment from Sanofi Milestone further demonstrates advancement of EVT Innovate initiative “TARGETBCD”

Topics: Corporate, Evotec, Sanofi, TARGETBCD, diabetes, beta cell replacement Read More

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Acceleration of research and development (“R&D”) of novel anti-infectives 100 employees will join Evotec Sanofi will license more than 10 infectious disease (“ID”) R&D assets Sanofi to provide significant support to Evotec including a one-time, upfront payment of € 60 M to support progression of a ...

Topics: Corporate, Evotec, Sanofi, infectious diseases Read More

Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi

Hamburg, Germany and Vienna, Austria, 08 January 2018: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and APEIRON Biologics AG, a company focused on cancer immunotherapy, announced today that the companies received the first milestone payment from Sanofi under a 3 party ...

Topics: Corporate, immuno-oncology, Apeiron, Sanofi, pre-clinical development Read More

Most Read

Posts by Topic